Cognition Therapeutics, Inc. (CGTX) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the Cognition Therapeutics fourth quarter and full year 2024 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Mike Moyer, with LifeSci Advisors. Thank you. You may begin. Thank you, operator, and good morning, everyone. Welcome to Cognition Therapeutics' fourth quarter and year-end 2024 results conference call. With me today are Lisa Ricciardi, President and Chief Executive Officer, John Doyle, Chief Financial Officer, and Dr. Tony Caggiano, Chief Medical Officer. This morning, the company issued a press release detailing its 2024 fourth quarter and year-end results. We encourage everyone to read this morning's press release as well as Cognition's annual report and Form 10-K, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for 30 days. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call management will be making forward looking statements. Actual results could differ materially from those stated or implied by these forward looking statements due to the risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Cognition's press releases and SEC filings, including its annual ...